11C-胆碱PET/CT可预测PSA<1 ng/ml前列腺癌患者的生存
该回顾性研究纳入210例根治性前列腺切除术后生化失败且PSA<1 ng/ml的患者,评估11C-胆碱PET/CT对前列腺癌特异性生存的预测价值。中位随访6.9年,PET/CT阳性率20.5%,阳性者中位生存13.4年,阴性者未达到中位生存,多因素分析仅PET/CT阳性显著预测生存(HR=2.54)。
要点
- PSA<1 ng/ml时11C-胆碱PET/CT阳性率20.5%,但阳性仍显著预测前列腺癌特异性生存。
- PET/CT阳性者10年生存率63.6%,阴性者86.0%,阳性者中位生存13.4年。
- 前列腺床或盆腔淋巴结摄取者生存优于骨骼摄取者。
核心结论
- 尽管PSA<1 ng/ml时11C-胆碱PET/CT阳性检出率相对较低,但阳性结果可预测该低PSA区间患者的前列腺癌特异性生存。
- 在更敏感的放射性示踪剂(如68Ga-PSMA-11)未广泛可用前,结果可能支持在PSA<1 ng/ml再分期中更广泛使用放射性标记胆碱。
研究设计与样本
- 采用Kaplan-Meier曲线估计前列腺癌特异性生存,Cox回归分析评估临床病理变量与生存的关联。
主要发现
- 根治性前列腺切除术后中位随访6.9年(95%CI 2.0-14.5年),11C-胆碱PET/CT阳性率为20.5%。
- PET/CT阳性患者中位前列腺癌特异性生存13.4年(95%CI 9.9-16.8年),阴性患者未达到中位生存(log-rank卡方=15.0,P<0.001)。
- PET/CT阴性者和阳性者的10年生存概率分别为86.0%(95%CI 80.7%-91.3%)和63.6%(95%CI 54.5%-72.7%)。
- 多因素分析中仅11C-胆碱PET/CT显著预测前列腺癌特异性生存(HR=2.54,95%CI 1.05-6.13,P=0.038)。
- 前列腺床或盆腔淋巴结病理性11C-胆碱摄取者的前列腺癌特异性生存长于骨骼病理性摄取者(log-rank卡方=27.4,P<0.001)。
关键数值与推荐
- 11C-胆碱PET/CT阳性定义为存在病理性示踪剂摄取。
- 前列腺癌特异性生存计算为从根治性前列腺切除术至前列腺癌特异性死亡的时间间隔。
临床怎么用
- 对根治性前列腺切除术后生化失败且PSA<1 ng/ml的患者,可考虑行11C-胆碱PET/CT再分期以获取预后信息。
- PET/CT阳性尤其骨骼摄取提示生存较差,可能需要更密切随访或强化治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The main drawback of 11C-choline PET/CT for restaging prostate cancer (PCa) patients with biochemical failure is the relatively low positive detection rate for prostate specific antigen (PSA) < 1 ng/ml. This study assessed whether 11C-choline PET/CT predicts survival in PCa patients with PSA < 1 ng/ml. METHODS: This retrospective study included 210 PCa patients treated with radical prostatectomy who underwent 11C-choline PET/CT from December 1, 2004 to July 31, 2007 due to biochemical failure. PCa-specific survival was estimated using Kaplan-Meier curves. Cox regression analysis was used to evaluate the association between clinicopathologic variables and PCa-specific survival. PCa-specific survival was computed as the interval from radical prostatectomy to PCa-specific death. RESULTS: Median follow-up after radical prostatectomy was 6.9 years (95% confidence interval, CI, 2.0-14.5 years). 11C-choline PET/CT was positive in 20.5% of patients. Median PCa-specific survival was 13.4 years (95% CI, 9.9-16.8 years) in patients with positive 11C-choline PET/CT, and it was not achieved in patients with negative 11C-choline PET/CT (log-rank, chi-square = 15.0, P < 0.001). Ten-year survival probabilities for patients with negative 11C-choline PET/CT and for patients with positive 11C-choline PET/CT were 86.0% (95% CI: 80.7%-91.3%) and 63.6% (95% CI: 54.5-72.7%). At multivariate analysis, only 11C-choline PET/CT significantly predicted PCa-specific survival (hazard ratio = 2.54, 95% CI, 1.05-6.13, P = 0.038). Patients with pathological 11C-choline uptake in the prostatic bed or in pelvic lymph nodes had longer PCa-specific survival in comparison to patients with pathological tracer uptake in the skeleton (log-rank: chi-square = 27.4, P < 0.001). CONCLUSION: Despite the relatively low positive detection rate for PSA < 1 ng/ml, positive 11C-choline PET/CT predicts PCa-specific survival in this low PSA range. As long as more sensitive radiotracers, such as 68Ga-PSMA-11, do not become more widely available, these results might support a broader use of radiolabeled choline in restaging PCa for PSA < 1 ng/ml.
引用
- Giovacchini G, Guglielmo P, Mapelli P, et al. 11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml. Eur J Nucl Med Mol Imaging. 2019. PMID: 30631911. doi:10.1007/s00259-018-4253-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。